This study found that HIV-1 could be eliminated in mice using a combination of two antiviral technologies—long-acting viral reservoir–targeted antiretroviral therapy and CRISPR/Cas-9 gene editing. HIV was undetectable in 9 out of 23 mice that received the combination treatment. HIV was not eliminated in any of the mice that were given either treatment alone.
Treatment for alcohol and opioid use disorders (AOUD) is feasible in primary care settings, but ongoing funding to support organizational capacity is critical for sustaining such programs.
Mindful Awareness in Body-Oriented Therapy (MABT) improved emotion regulation, reduced craving, and promoted abstinence in women with a history of trauma and emotional problems receiving outpatient treatment for substance use disorder.
Interim treatment with buprenorphine significantly improved the psychiatric symptoms of people awaiting comprehensive treatment for opioid use disorder (OUD). Buprenorphine treatment, even without concurrent psychosocial counseling, may help patients with no, or delayed, access to comprehensive OUD treatment.
A recent NIDA-sponsored study found higher rates of NAS among males than among females. A second study found that, among infants whose mothers were treated with buprenorphine while pregnant, NAS was more severe among those whose mothers used other substances.
Mindfulness-Oriented Recovery Enhancement (MORE) reduces opioid misuse among chronic pain patients. MORE shifts patients' attention away from drug cues and toward cues for natural rewards.
Smokers who switch to cigarettes with very low nicotine content may experience mild and transient increases in some withdrawal symptoms. Cigarettes with reduced nicotine will be easier to quit than the cigarettes marketed at present.
Several effective medications are now available for treating opioid use disorder but many patients who could benefit do not receive them. Some patients who receive the medications face challenges to staying in treatment.